Table 2 HCC Tumor characteristics of the studied patients.
Variables | Patients with HCC treated with sorafenib | ||
|---|---|---|---|
Count | % | ||
Tumor size (median (IQR)) in cm | 7.00 (5.00–10.00) | ||
Number of Focal lesions | Single | 392 | 55.5% |
Two | 104 | 14.7% | |
Three | 34 | 4.8% | |
Multiple | 176 | 24.9% | |
Tumor site | Right lobe | 508 | 72.0% |
Left lobe | 86 | 12.2% | |
Both lobes | 112 | 15.9% | |
Portal vein status | Patent | 469 | 66.4% |
Segmental | 1 | 0.1% | |
Thrombosed main portal vein | 193 | 27.3% | |
Right PVT | 30 | 4.2% | |
Left PVT | 9 | 1.3% | |
Right and Left PVT | 3 | 0.4% | |
SMV thrombosis | 1 | 0.1% | |
Malignant lymphadenopathy | 188 | 26.6% | |
hepatic vein thrombosis | 31 | 4.4% | |
Extra hepatic spread | Bone | 6 | 0.8% |
Bone, Suprarenal, Peritoneal | 1 | 0.1% | |
Lung | 18 | 2.5% | |
Lung and Bone | 7 | 1.0% | |
Suprarenal | 2 | 0.3% | |
no | 672 | 95.2% | |
BCLC staging | B | 420 | 59.5% |
C | 286 | 40.5% | |
